Serum total and HDL cholesterol and risk of prostate cancer

Cancer Causes and Control

Volumn 22, Issue 11, 2011, Pages 1545-1552

  Mondul, Alison M ^a   Weinstein, Stephanie J ^a   Virtamo, Jarmo ^b   Albanes, Demetrius ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Biomarker; Cholesterol; Epidemiology; HDL; Molecular; Prospective studies; Prostatic neoplasms; Risk

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK REDUCTION; SMOKING;

AGED; ALPHA-TOCOPHEROL; BETA CAROTENE; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; DOUBLE-BLIND METHOD; FINLAND; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 82955161723     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-011-9831-7     Document Type: Article

References (33)

1. Platz EA, Clinton SK, Giovannucci E (2008) Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123(7):1693-1698
2. Platz EA, Till C, Goodman PJ, et al (2009) Men with low serum cholesterol have a lower risk of high grade prostate cancer in the Prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (in press)
3. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA (2010) Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 21(1):61-68. Available from http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation &list-uids=19806465
4. Shannon J, Tewoderos S, Garzotto M et al (2005) Statins and prostate cancer risk: A case-control study. Am J Epidemiol 162(4):318-325 (Pubitemid 41389713)
5. Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24): 1819-1825 (Pubitemid 46017933)
6. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16(11):2213-2217 (Pubitemid 351196351)
7. Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16(11):2226-2232 (Pubitemid 351196353)
8. Flick ED, Habel LA, Chan KA, et al (2007) Statin use and risk of prostate cancer in the California men's health study cohort. Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16(11):2218-2225 (Pubitemid 351196352)
9. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168(3): 250-260 (Pubitemid 352019786)
10. Friedman GD, Flick ED, Udaltsova N, Chan Pharm DJ, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 17(1):27-36 (Pubitemid 351166615)
11. Kark JD, Smith AH, Hames CG (1982) Serum retinol and the inverse relationship between serum cholesterol and cancer. British Med J (Clinical research ed.) 284(6310):152-154 (Pubitemid 12171751)
12. Wallace RB, Rost C, Burmeister LF, Pomrehn PR (1982) Cancer incidence in humans: relationship to plasma lipids and relative weight. J Natl Cancer Inst 68(6):915-918 (Pubitemid 12040914)
13. Hiatt RA, Fireman BH (1986) Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis 39(11):861-870 (Pubitemid 17229983)
14. Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, HakamaM(1988) Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 41(6):519-530
15. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL (1989) Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 129(3):511-517
16. Chyou PH, Nomura AM, Stemmermann GN, Kato I (1992) Prospective study of serum cholesterol and site-specific cancers. J Clin Epidemiol 45(3):287-292
17. Smith GD, Shipley MJ, Marmot MG, Rose G (1992) Plasma cholesterol concentration and mortality. The whitehall study. JAMA J Am Med Assoc 267(1):70-76
18. Schuit AJ, Van Dijk CE, Dekker JM, Schouten EG, Kok FJ (1993) Inverse association between serum total cholesterol and cancer mortality in dutch civil servants. Am J Epidemiol 137(9): 966-976 (Pubitemid 23191064)
19. Steenland K, Nowlin S, Palu S (1995) Cancer incidence in the national health and nutrition survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology; Cancer epidemiology, biomarkers & prevention : A publication of the America(TRUNCATED) 4(8):807-811
20. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F (2000) Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clinl Nutr 71(2):569-574 (Pubitemid 30061238)
21. Wuermli L, Joerger M, Henz S et al (2005) Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8(4):316-320 (Pubitemid 43078165)
22. Bravi F, Scotti L, Bosetti C et al (2006) Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO 17(6):1014-1017 (Pubitemid 43778996)
23. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE (2008) Hypercholesterolemia and prostate cancer: A hospital-based case-control study. Cancer Causes Control 19(10): 1259-1266. Available from http://www.ncbi.nlm.nih. gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list- uids= 18704722
24. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 20(7):1181-1192. Available from http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt= Citation&list-uids=19277881
25. Tuohimaa P, Tenkanen L, Syvala H, et al (2007) Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(2): 302-307. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids= 17301263 (Pubitemid 46383350)
26. Van Hemelrijck M, Walldius G, Jungner I, et al (2011) Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 22(7):1011-1019. Available from http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt= Citation&list-uids=21562751
27. Ahn J, Lim U, Weinstein SJ, et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18(11):2814-2821. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve& db=PubMed&dopt=Citation&list-uids= 19887581
28. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J (2002) The finnish cancer registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 41(4):381-388. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids= 12234031
29. Edwards JE, Moore RA (2003) Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 4:18
30. Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab TEM 19(4):113-121 (Pubitemid 351608305)
31. Kwiterovich PO Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol 86(12A):5L-10L. Available from http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve& db=PubMed&dopt=Citation&list-uids=11374859
32. Sekine Y, Demosky SJ, Stonik JA, et al (2010) High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res 8(9):1284-1294. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&dopt=Citation&list-uids=20671065
33. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A (2003) Contamination by opportunistic screening in the European randomized study of prostate cancer screening. BJU Int 92(Suppl 2): 97-100. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids= 14983964 (Pubitemid 38091150)